Meeting
2015 ASCO Annual Meeting
ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Authors
Mansoor Raza Mirza
NSGO, Copenhagen University Hospital, Copenhagen, Denmark
Mansoor Raza Mirza , Christiane Ehlers Mortensen , Elisabeth Avall-Lundqvist , Line Bjorge , Jonathan S. Berek , Jorn Herrstedt , Anne Juul Holm , Tinne Kirkegaard , Johanna Maenpaa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02354131
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS5607)
DOI
10.1200/jco.2015.33.15_suppl.tps5607
Abstract #
TPS5607
Poster Bd #
164a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6).
First Author: JUNG-YUN LEE
Poster
2015 ASCO Annual Meeting
Multicenter randomized Phase II study of AZD1775 plus chemotherapy versus chemotherapy alone in patients with platinum-resistant TP53-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer.
First Author: Kathleen N. Moore
Poster
2023 ASCO Annual Meeting
GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
First Author: David M. O'Malley
Poster
2023 ASCO Annual Meeting
Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients.
First Author: Olga Zamulko